| Big physics, small doses: the use of AMS and PET in human microdosing of development drugs G Lappin, RC Garner Nature reviews drug discovery 2 (3), 233-240, 2003 | 301 | 2003 |
| Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs G Lappin, W Kuhnz, R Jochemsen, J Kneer, A Chaudhary, B Oosterhuis, ... Clinical Pharmacology & Therapeutics 80 (3), 203-215, 2006 | 271 | 2006 |
| Sulforaphane and quercetin modulate PhIP–DNA adduct formation in human HepG2 cells and hepatocytes JR Bacon, G Williamson, RC Garner, G Lappin, S Langouet, Y Bao Carcinogenesis 24 (12), 1903-1911, 2003 | 150 | 2003 |
| Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability G Lappin, Y Shishikura, R Jochemsen, RJ Weaver, C Gesson, B Houston, ... European journal of pharmaceutical sciences 40 (2), 125-131, 2010 | 127 | 2010 |
| Microdosing and drug development: past, present and future G Lappin, R Noveck, T Burt Expert opinion on drug metabolism & toxicology 9 (7), 817-834, 2013 | 107 | 2013 |
| The phase 0 microdosing concept RC Garner, G Lappin British journal of clinical pharmacology 61 (4), 367, 2006 | 99 | 2006 |
| The utility of microdosing over the past 5 years G Lappin, RC Garner Expert Opinion on Drug Metabolism & Toxicology 4 (12), 1499-1506, 2008 | 96 | 2008 |
| Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry G Lappin, RC Garner Analytical and bioanalytical chemistry 378 (2), 356-364, 2004 | 96 | 2004 |
| Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics G Lappin, L Stevens Expert Opinion on Drug Metabolism & Toxicology 4 (8), 1021-1033, 2008 | 92 | 2008 |
| The use of isotopes in the determination of absolute bioavailability of drugs in humans G Lappin, M Rowland, RC Garner Expert opinion on drug metabolism & toxicology 2 (3), 419-427, 2006 | 90 | 2006 |
| Microdosing and other phase 0 clinical trials: facilitating translation in drug development T Burt, K Yoshida, G Lappin, L Vuong, C John, SN De Wildt, Y Sugiyama, ... Clinical and translational science 9 (2), 74, 2016 | 84 | 2016 |
| The Application of Accelerator Mass Spectrometry to Absolute Bioavailability Studies in Humans: Simultaneous Administration of an Intravenous Microdose of 14C … N Sarapa, PH Hsyu, G Lappin, RC Garner The Journal of Clinical Pharmacology 45 (10), 1198-1205, 2005 | 75 | 2005 |
| Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human … G Lappin, Y Shishikura, R Jochemsen, RJ Weaver, C Gesson, ... European journal of pharmaceutical sciences 43 (3), 141-150, 2011 | 67 | 2011 |
| Radiotracers in drug development G Lappin, S Temple CRC Press, 2006 | 62 | 2006 |
| A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects A Madan, Z O'Brien, J Wen, C O'Brien, RH Farber, G Beaton, P Crowe, ... British journal of clinical pharmacology 67 (3), 288-298, 2009 | 58 | 2009 |
| The use of accelerator mass spectrometry to obtain early human ADME/PK data G Lappin, RC Garner Expert opinion on drug metabolism & toxicology 1 (1), 23-31, 2005 | 56 | 2005 |
| Biotransformation of monoterpenoids by suspension cultures of Lavandula angustifolia GJ Lappin, JD Stride, J Tampion Phytochemistry 26 (4), 995-997, 1987 | 52 | 1987 |
| Positron emission tomography for use in microdosing studies. CC Wagner, M Müller, G Lappin, O Langer Current Opinion in Drug Discovery & Development 11 (1), 104-110, 2008 | 51 | 2008 |
| Absolute oral bioavailability and metabolic turnover of β-sitosterol in healthy subjects G Duchateau, B Cochrane, S Windebank, J Herudzinska, D Sanghera, ... Drug Metabolism and Disposition 40 (10), 2026-2030, 2012 | 49 | 2012 |
| Comparative metabolism of 2, 4-dichlorophenoxyacetic acid (2, 4-D) in rat and dog B Van Ravenzwaay, TD Hardwick, D Needham, S Pethen, GJ Lappin Xenobiotica 33 (8), 805-821, 2003 | 49 | 2003 |
